News Website

Woodbridge Trader Joes On Rt. 1 Announces Opening Date - Patch

Woodbridge Trader Joes On Rt. 1 Announces Opening Date Patch

Published: Oct. 24, 2025, 2:40 p.m.

Read Full Article

Women’s health is not niche: It’s the future of healthcare - FemTech World

Women’s health is not niche: It’s the future of healthcare FemTech World

Published: Oct. 24, 2025, 1:03 p.m.

Read Full Article

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis Cell Communication and Signaling

Published: Oct. 24, 2025, 12:50 p.m.

Read Full Article

Low-Dose Dienogest: 48 Weeks of Endometriosis Relief - Bioengineer.org

Low-Dose Dienogest: 48 Weeks of Endometriosis Relief Bioengineer.org

Published: Oct. 24, 2025, 11:21 a.m.

Read Full Article

Treatment paradigm for recurrent endometriosis shifts from surgery to medication - koreabiomed.com

Treatment paradigm for recurrent endometriosis shifts from surgery to medication koreabiomed.com

Published: Oct. 24, 2025, 8:01 a.m.

Read Full Article

Do you have endometriosis? - Curtin University

Do you have endometriosis? Curtin University

Published: Oct. 24, 2025, 4:13 a.m.

Read Full Article

Do you have endometriosis? | News at Curtin - Curtin University

Do you have endometriosis? | News at Curtin Curtin University

Published: Oct. 24, 2025, 4:13 a.m.

Read Full Article

October Prime Day Ninja deals: CREAMi, Crispi, and more - Mashable

October Prime Day Ninja deals: CREAMi, Crispi, and more Mashable

Published: Oct. 24, 2025, 12:32 a.m.

Read Full Article

Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosi - Cureus

Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosi Cureus

Published: Oct. 24, 2025, 12:29 a.m.

Read Full Article

Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.

Dienogest (DNG) is widely used to manage endometriosis-associated pain; however, long-term data comparing low and standard doses are limited. Therefore, this study aimed to evaluate the efficacy and safety of …

Published: Oct. 24, 2025, midnight

Read Full Article

Endometriosis; dysmenorrhea; dienogest; clinical trial; open Label

Latest Articles

Woodbridge Trader Joes On Rt. 1 Announces Opening Date - Patch

Women’s health is not niche: It’s the future of healthcare - FemTech World

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Low-Dose Dienogest: 48 Weeks of Endometriosis Relief - Bioengineer.org

Treatment paradigm for recurrent endometriosis shifts from surgery to medication - koreabiomed.com

Do you have endometriosis? - Curtin University

Do you have endometriosis? | News at Curtin - Curtin University

October Prime Day Ninja deals: CREAMi, Crispi, and more - Mashable

Primary Invasive Squamous Cell Carcinoma of the Vagina Presenting Three Decades After Total Hysterectomy for Benign Endometriosi - Cureus

Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.

Subscribe to Our Newsletter